Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Myelodysplastic Syndromes 3Small Cell Lung Carcinoma 2Melanoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Rectal Diseases 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lung Neoplasms 1Kidney Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1

Interventions

Gemcitabine 8pembrolizumab 5Cisplatin 5enfortumab vedotin 3avelumab 3Specimen Handling 3Nivolumab 3Magnetic Resonance Spectroscopy 3Carboplatin 3vinflunine 2Radiotherapy 2Nephroureterectomy 2Immunoglobulin G 2Doxorubicin 2Disulfides 2vandetanib 1tremelimumab 1tocilizumab 1tamibarotene 1relatlimab 1pegfilgrastim 1merphos 1guadecitabine 1genexol-PM 1enzalutamide 1durvalumab 1dehydroftorafur 1atezolizumab 1abexinostat 1Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ureteral Neoplasms × guadecitabine × Clear all
NCT03179943 2021-11-04

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Fox Chase Cancer Center

Phase 2 Active not recruiting
21 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡